Cadence Applies for FDA Approval

Luke Timmerman5/14/09

Cadence Pharmaceuticals (NASDAQ: CADX), the San Diego-based developer of a new pain medication, said today it has filed an application to seek FDA approval to start selling it in the U.S. The drug, an intravenous form of acetaminophen with the trade name of Acetavance, reached its goal of providing pain relief in a clinical trial. If approved, it would be the first new IV pain reliever approved in the U.S. in more than 20 years, the company said.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.